Peptide Reference Desk
Hexarelin vs Ipamorelin: potency and selectivity depend on the assay
Hexarelin and Ipamorelin are ghrelin-receptor secretagogues, but online rankings often ignore receptor panels, endocrine endpoints and study design.
“Stronger” is not a complete result
Hexarelin and Ipamorelin are commonly compared within GHSR-1a research. A larger response in one assay does not establish a better molecule. Potency, efficacy, selectivity and duration are separate measurements.
What to pull from the methods section
- Receptor construct, species and cell system.
- Concentration range and reference agonist.
- Which endocrine or off-target endpoints were measured.
- Sampling time and exposure.
Without those details, “Ipamorelin is selective” and “Hexarelin is potent” are advertising-sized summaries.
Identity still comes first
Each compound needs its own sequence, expected mass, LC-MS result, purity method, content and counterion. Shared receptor activity cannot qualify a mislabeled lot, and combination anecdotes are not controlled evidence.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.